v2.4.0.6
Segment information (Details) (USD $)
In Millions, unless otherwise specified
 3 Months Ended 12 Months Ended
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Revenues [Abstract]                      
Product sales $ 4,337 $ 4,201 $ 4,200 $ 3,901 $ 3,907 $ 3,877 [1] $ 3,893 $ 3,618 $ 16,639 $ 15,295 $ 14,660
Other revenues                 626 287 393
Total revenues                 17,265 15,582 15,053
Neulasta [Member]
                      
Revenues [Abstract]                      
Product sales                 4,092 3,952 3,558
NEUPOGEN [Member]
                      
Revenues [Abstract]                      
Product sales                 1,260 1,260 1,286
ENBREL [Member]
                      
Revenues [Abstract]                      
Product sales                 4,236 3,701 3,534
Aranesp [Member]
                      
Revenues [Abstract]                      
Product sales                 2,040 2,303 2,486
EPOGEN [Member]
                      
Revenues [Abstract]                      
Product sales                 1,941 2,040 2,524
Sensipar Mimpara [Member]
                      
Revenues [Abstract]                      
Product sales                 950 808 714
Vectibix [Member]
                      
Revenues [Abstract]                      
Product sales                 359 322 288
Nplate [Member]
                      
Revenues [Abstract]                      
Product sales                 368 297 229
XGEVA [Member]
                      
Revenues [Abstract]                      
Product sales                 748 351 8
Prolia [Member]
                      
Revenues [Abstract]                      
Product sales                 472 203 33
Other [Member]
                      
Revenues [Abstract]                      
Product sales                 $ 173 $ 58 $ 0
[1] We recorded a $780 million legal settlement charge ($705 million, net of tax) in connection with an agreement in principle to settle allegations related to our sales and marketing practices.